Sign Out
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with chemotherapy, in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease, in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
Lanjutkan dengan Google